M.t.e Pathogenix

Company Overview

Snapshot

Founded in February 2025, M.t.e Pathogenix operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its AI-powered indoor air monitoring device.

Business overview

M.t.e Pathogenix, also known as Pathogenix.AI (Senzi.me), specializes in Health Tech & Life Sciences, specifically within Medical Devices and Diagnostics Devices. The company develops an AI-powered indoor air monitoring device designed to detect and neutralize airborne pathogens and pollutants in near real-time. This technology targets both homes and commercial environments, including healthcare, education, and transportation, aiming to reduce exposure risk by providing alerts and actionable air-safety insights. The solution is presented as a plug-in monitor with minimal setup, emphasizing rapid detection for healthier indoor spaces.

Company Intelligence Q&A

What is M.t.e Pathogenix's primary product?

M.t.e Pathogenix develops an AI-powered indoor air monitoring device designed for real-time detection and neutralization of airborne pathogens and pollutants.

When was M.t.e Pathogenix founded?

M.t.e Pathogenix was founded in February 2025.

What markets does M.t.e Pathogenix target?

M.t.e Pathogenix targets both residential homes and commercial environments such as healthcare facilities, educational institutions, and transportation hubs.

What is the current product stage of M.t.e Pathogenix?

M.t.e Pathogenix's product is currently in the Released stage, indicating it is available to customers.

What business models does M.t.e Pathogenix utilize?

M.t.e Pathogenix operates under both B2C (Business-to-Consumer) and B2B (Business-to-Business) models.